Hidehito HORINOUCHI· @HHorinouchi · X·· 21 小时前评分70
正文 · 机器翻译
🆙#ESMO26 快速口头报告 I：#LCSM 转移瘤
🔥Telisotuzumab Adizutecan 在非鳞状非小细胞肺癌（NSQ NSCLC）患者（Pts）中的总体生存期（OS）分析：I 期首次人体研究
🎙️Dr. David Sommerhalder
🔢2658RO
🎯在既往接受过多线治疗的患者中，中位 OS 为 13.8 个月（EGFR WT，n=48）和 16.2 个月（EGFR MUT，n=41）
🎯c-Met 高表达患者的 OS 更长（25.2 个月，EGFR WT ≥3+/≥10%）
☑️NCT05029882
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255
@OncoAlert @Larvol @myESMO @IASLC
90 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
2658RO按 Rapid oral 1: NSCLC, metastatic 对上
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study 🎙️Dr. David Sommerhalder 🔢2658RO 🎯Median OS 13.8mo (EGFR WT, n=48) and 16.2mo (EGFR MUT, n=41) in Heavily Pretreated Pts 🎯Longer OS in High c-Met Expressers (25.2mo, EGFR WT ≥3+/≥10%) ☑️NCT05029882 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com